Loading organizations...
Loading organizations...
Phenomix is a technology company.
Phenomix Sciences operates as a precision obesity medicine company, developing and applying advanced technology to personalize treatment approaches. The company's core offering involves a proprietary blood test and AI models that combine genomic, phenotypic, and biomarker data. This integrated approach aims to classify individuals into distinct obesity subtypes, enabling clinicians to identify the most effective interventions for each patient based on their unique biological profile.
The company was co-founded in 2017 by Andres Acosta and Michael Camilleri. Their foundational insight stemmed from the understanding that obesity is a heterogeneous disease, requiring a more nuanced, individualized approach beyond conventional treatments. Leveraging their clinical and research backgrounds, they established Phenomix Sciences to bring this phenotyping-driven methodology to medical practice.
Phenomix Sciences serves healthcare providers who seek to enhance outcomes for patients struggling with obesity. Its vision centers on transforming obesity care by providing actionable data that guides treatment decisions, thereby moving away from a one-size-fits-all paradigm. The company is committed to advancing the understanding and management of obesity through personalized, data-driven solutions.
Phenomix has raised $96.8M across 5 funding rounds.
Phenomix has raised $96.8M in total across 5 funding rounds.
# Phenomix Sciences: Precision Obesity Medicine Pioneer
Phenomix Sciences is a precision obesity biotechnology company, not a traditional technology company, though it leverages advanced AI and machine learning technologies. Founded in 2024, Phenomix transforms obesity treatment by delivering individualized insights into how patients respond to specific weight loss interventions.[1] The company's core product, the MyPhenome® test, uses DNA analysis and AI to predict patient response to various obesity treatments—from GLP-1 medications to bariatric procedures—enabling clinicians to match patients with interventions most likely to succeed.[3]
The company serves physicians, patients, and pharmaceutical/medical device partners seeking to move beyond trial-and-error obesity care. Phenomix addresses a critical gap in modern medicine: while new obesity medications have emerged, clinicians lack tools to predict which patients will respond to which treatments. According to Mayo Clinic research underlying Phenomix's technology, patients who were phenotyped achieved 2x greater weight loss than those who were not, demonstrating the tangible impact of precision matching.[4]
Phenomix's technology is rooted in rigorous research from Mayo Clinic, with the company's technology exclusively licensed from the institution.[1] The founding emerged from recognition that obesity rates have doubled over the past 20 years, with projections suggesting 50% of the adult population will be obese by 2030 without intervention.[4] Rather than developing new medications, Phenomix's founders recognized that phenotyping—understanding an individual's unique genetics, microbiome, and metabolism—could enable tailored treatment selection.
The company launched in 2024 with significant backing from strategic investors including Health2047 (a venture studio founded by the American Medical Association), DexCom, Inc., and Labcorp.[1] The MyPhenome test was named one of TIME's Best Inventions of 2024, signaling early market validation and recognition.[1] Co-founders were awarded the first patent for using precision medicine and phenotyping to treat obesity.[2]
Phenomix operates at the intersection of three powerful trends: the precision medicine revolution, the obesity epidemic, and the rise of GLP-1 therapeutics. As obesity medications gain mainstream adoption, the critical bottleneck shifts from drug availability to treatment selection—exactly where Phenomix's technology intervenes.
The company exemplifies how AI and genomics are moving from research into clinical practice. Rather than building another drug or device, Phenomix creates the diagnostic infrastructure that makes existing and future treatments more effective. This positions it within the broader shift toward trait-based, personalized medicine—a model that has transformed oncology and is now expanding into metabolic disease.
Phenomix also strengthens the Mayo Clinic innovation ecosystem, demonstrating how academic medical centers can commercialize research through strategic partnerships. The backing of Health2047 (an AMA-affiliated venture studio) signals institutional commitment to reshaping healthcare delivery through precision diagnostics.
Phenomix is well-positioned to become the standard diagnostic tool in obesity medicine as GLP-1 adoption accelerates and clinicians seek to optimize treatment selection. The company's near-term focus will likely involve expanding clinical adoption, building payer reimbursement pathways, and deepening partnerships with pharmaceutical companies conducting obesity trials.
The broader opportunity lies in expanding phenotyping beyond treatment selection into prevention and long-term management. As the company's platform "keeps uncovering new insights," it may evolve toward predicting obesity risk, identifying optimal lifestyle interventions, and enabling truly preventive obesity care.[3]
The timing is critical: with obesity rates accelerating and new medications entering the market, Phenomix captures a moment when precision diagnostics can reshape an entire disease category. Success here could establish a template for precision medicine in other metabolic and chronic diseases.
Phenomix has raised $96.8M in total across 5 funding rounds.
Phenomix's investors include Dexcom Ventures, Health2047, Labcorp, National Institutes of Health, 5AM Ventures.
Phenomix has raised $96.8M across 5 funding rounds. Most recently, it raised $7.8M Phenomix Sciences - Grant / Series A in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 16, 2024 | $7.8M Phenomix Sciences - Grant / Series A | Dexcom Ventures, Health2047, Labcorp, National Institutes of Health | |
| Mar 1, 2007 | $55.0M Series C | 5AM Ventures | |
| Apr 1, 2005 | $20.0M Series B | 5AM Ventures | |
| Jul 1, 2004 | $2.0M Series A | 5AM Ventures | |
| Jun 1, 2003 | $12.0M Series A | 5AM Ventures |